{"id":"87b7b2a9ee98","type":"article","url":"https://hartvaat.nl/2026/02/05/tenecteplase-bij-basilarisocclusie-tot-24-uur-veelbelovende-lancet-data/","title":"Tenecteplase bij basilarisocclusie tot 24 uur: veelbelovende Lancet-data","title_en":"Intravenous tenecteplase for acute ischaemic stroke within 24 h due to basilar artery occlusion","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":[],"journal":"The Lancet","doi":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00139-X/fulltext","source_url":"https://doi.org/https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00139-X/fulltext","authors":["Georgios Tsivgoulis","Lina Palaiodimou","Guillaume Turc"],"significance":9,"published":"2026-02-05","source_date":"2026-02-05","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"This Lancet publication addresses basilar artery occlusion, the most severe presentation of large-vessel ischemic stroke, with new randomized and observational evidence supporting intravenous tenecteplase therapy within an extended 24-hour treatment window.","created":"2026-07-03T10:25:05Z","updated":"2026-07-03T13:24:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Basilarisocclusie is de ernstigste presentatie van ischemisch CVA door groot-vaatocclusie. Nieuwe gerandomiseerde en observationele data in The Lancet ondersteunen de superioriteit van tenecteplase boven alteplase bij deze patiënten, ook buiten het conventionele tijdvenster van 4,5 uur.","abstract_original":"Basilar artery occlusion is a devastating condition with dismal prognosis and constitutes the most severe presentation of acute ischaemic stroke due to large-vessel occlusion.1 Randomised evidence on the safety and efficacy of intravenous thrombolysis in this stroke subtype is scarce, especially outside the conventional 0–4·5 h window.1,2 Tenecteplase is a third-generation tissue plasminogen activator with higher fibrin specificity and longer half-life than alteplase.3 Accruing randomised and observational evidence supports the superiority of tenecteplase over alteplase in patients who have had an acute ischaemic stroke, particularly those with large-vessel occlusion, in improving 3-month functional outcome assessed by the modified Rankin scale (mRS) score."}